SCHEDULE: Vanguard Discloses 5.3% Stake in Intellia Therapeutics

Vanguard Portfolio Management has reported a beneficial ownership of 5.3% of Intellia Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Portfolio Management, along with its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, has disclosed a beneficial ownership of 6,266,007 shares of Intellia Therapeutics Inc. common stock.
• This holding represents 5.3% of the total class of securities.
• The filing indicates that Vanguard Portfolio Management has sole dispositive power over 6,266,007 shares and sole voting power over 42,682 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal due to the substantial investment by a reputable institutional investor like Vanguard, suggesting confidence in Intellia's technology and future potential.

Positives

• Vanguard, a major institutional investor, has taken a significant stake in Intellia Therapeutics, indicating confidence in the company's long-term prospects.
• The disclosure of sole dispositive power suggests a clear investment strategy and control over the shares held.

Risks

• The filing does not contain specific risk factors related to Intellia Therapeutics; it is a Schedule 13G filing by an institutional investor.
• Potential future changes in Vanguard's investment strategy could lead to significant selling pressure on Intellia's stock.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Intellia Therapeutics. It is a disclosure of ownership by Vanguard.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Portfolio Management LLC and the following affiliates of Vanguard Portfolio Management LLC or business divisions of such affiliates: Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a significant stake by a large asset manager like Vanguard in a gene-editing company like Intellia Therapeutics underscores the growing institutional interest and investment in the biotechnology sector, particularly in companies focused on novel therapeutic modalities.

Stakeholder Impact

• Shareholders: The investment by Vanguard may be seen as a positive endorsement, potentially increasing investor confidence and influencing share price.
• Management: The significant stake by a major investor may lead to increased scrutiny and engagement on strategic decisions.
• Creditors: A stable or increasing institutional investor base can be viewed favorably by creditors, potentially impacting the company's cost of capital.

Next Steps

• Continued monitoring of Vanguard's ownership levels in Intellia Therapeutics.
• Observation of Intellia Therapeutics' operational and clinical progress, which will influence Vanguard's ongoing investment decisions.

Key Dates

Recommendation

This filing indicates a significant institutional investment by Vanguard, which is a positive signal. However, it is a disclosure of past actions rather than a forward-looking statement about Intellia's performance. Therefore, a 'hold' recommendation is appropriate, pending further operational and clinical updates from Intellia Therapeutics itself.

Keywords

Intellia Therapeutics, Vanguard, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, CRISPR, Gene Editing